The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
Abstract
Purpose: Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC. Methods: Seventy-five patients with chemotherapy-naïve metastatic AIPC were randomly assigned to receive either docetaxel 30 mg/m 2 intravenously every week for 3 consecutive weeks, followed by a 1-week rest period (n = 25); or docetaxel at the same dose and schedule, plus thalidomide 200 mg orally each day (n = 50). Prostate-specific antigen (PSA) consensus criteria and radiographic scans were used to determine the proportion of patients with a PSA decline, and time to progression. Results: After a median potential follow-up time of 26.4 months, the proportion of patients with a greater than 50% decline in PSA was higher in the docetaxel/thalidomide group (53% in the combined group, 37% in docetaxel-alone arm). The median progression-free survival in the docetaxel group was 3.7 months and 5.9 months in the combined group (P = .32). At 18 months, overall survival in the docetaxel group was 42.9% and 68.2% in the combined group. Toxicities in both groups were manageable after administration of prophylactic low-molecular-weight heparin in the combination group. Conclusion: In this randomized phase II trial, the addition of thalidomide to docetaxel resulted in an encouraging PSA decline rate and overall median survival rate in patients with metastatic AIPC. After the prophylactic low-molecular-weight heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated. Larger randomized trials are warranted to assess the impact of this combination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
Weidner, N., Carroll, P. R., Flax, J. D., Blumenfeld, W., & Folkman, J. (1993) · PubMed Central · Cited by 1,620
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationBcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Figg, W. D., Dahut, W., Duray, P. H., Hamilton, M., Tompkins, A. C., Steinberg, S. M., Jones, E. C., Premkumar, A., Linehan, W. M., Floeter, M. K., et al. (2001) · PubMed · Cited by 330
Self-citationSavarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M.-E., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 323
Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Judge, T. W., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D. F., Fine, R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.958 · Cited by 311
Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
Bauer, K. S., Dixon, S. C., & Figg, W. D. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00046-x · Cited by 295
Self-citationActivity of Thalidomide in AIDS-Related Kaposi’s Sarcoma
Little, R. F., Wyvill, K. M., Pluda, J. M., Welles, L., Marshall, V., Figg, W. D., Newcomb, F. M., Tosato, G., Feigal, E., Steinberg, S. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2593 · Cited by 290
Self-citationZangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L., & Tricot, G. (2002) · Blood · doi:10.1182/blood-2002-01-0335 · Cited by 262
Picus, J., & Schultz, M. (1999) · PubMed · Cited by 245
Wakui, S., Furusato, M., Itoh, T., et al. (1992) · The Journal of Pathology · doi:10.1002/path.1711680303 · Cited by 234
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
Beer, T. M., Pierce, W. C., Lowe, B. A., & Henner, W. D. (2001) · Annals of Oncology · doi:10.1023/a:1012258723075 · Cited by 193
Friedland, D., Cohen, J., Miller, R., Voloshin, M., Gluckman, R. A., Lembersky, B. C., Zidar, B. L., Keating, M., Reilly, N., & Dimitt, B. (1999) · PubMed · Cited by 155
Topography of neovascularity in human prostate carcinoma
Siegal, J. A., Yu, E., & Brawer, M. K. (1995) · Cancer · doi:10.1002/1097-0142(19950515)75:10<2545::aid-cncr2820751022>3.0.co;2-x · Cited by 140
Sinibaldi, V. J., Carducci, M. A., Moore-Cooper, S., Laufer, M., ZAHURAK, M. L., & Eisenberger, M. A. (2002) · Cancer · doi:10.1002/cncr.10350 · Cited by 139
McDonnel, T. J., Navone, N. M., Troncoso, P., Pisters, L. L., Conti, C. J., von Eschenbach, A. C., Brisbay, S. M., & Logothetis, C. J. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)65204-2 · Cited by 137
Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
Marx, G. M., Pavlakis, N., McCowatt, S., Boyle, F. M., Levi, J. A., Bell, D. R., Cook, R., Biggs, M. T., Little, N., & Wheeler, H. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012554328801 · Cited by 128
Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Weitzman, A., Judge, T. W., England-Owen, C., Zuech, N., Pfaff, C., Newhouse, J. H., et al. (1999) · PubMed · Cited by 93
Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
Figg, W. D., Kruger, E. A., Price, D. K., Kim, S. S.-E., & Dahut, W. (2002) · Investigational New Drugs · doi:10.1023/a:1015626410273 · Cited by 88
Self-citationLissbrant, E. (2001) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655901753367532 · Cited by 63
Thalidomide: A novel template for anticancer drugs
Stirling, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90032-6 · Cited by 50
Horne, M. K., Figg, W. D., Arlen, P. M., Gulley, J. L., Parker, C., Lakhani, N. J., Parnes, H. L., & Dahut, W. L. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.3.315.32106 · Cited by 40
Self-citationAngiogenesis in urological malignancy: prognostic indicator and therapeutic target
Jones, & Fujiyama (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00018.x · Cited by 39
The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer
Retter, A. S., Figg, W. D., & Dahut, W. L. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.023 · Cited by 24
Self-citationRini, B. I., & Small, E. J. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200105000-00013 · Cited by 12
Cited by
Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 297
Self-citationArlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
Self-citationPhase I study of oral lenalidomide in patients with refractory metastatic cancer
Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335001 · Cited by 56
Self-citation
Metadata
- Authors
- Dahut, W. L., Gulley, J. L., Arlen, P. M., Liu, Y., Fedenko, K. M., Steinberg, S. M., Wright, J. J., Parnes, H., Chen, C. C., Jones, E., Parker, C. E., Linehan, W. M., & Figg, W. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-01
- Volume
- 22
- Issue
- 13
- Pages
- 2532-2539
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153140330
- Cited by
- 351
- References
- 33
- FWCI
- 31.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.